Gerald J. Yakatan

Contributor   in
Industry Trends  

Dr. Yakatan has served as Chairman & CEO of IRISYS since founding the Company in 1996. In addition to his leadership and oversight of IRISYS’ operations, Dr. Yakatan personally heads our Strategic Consulting services. He plans and engages in FDA meetings with U.S. and international clients, and interacts with high-level FDA personnel on their behalf.

Dr. Yakatan has decades of pharmaceutical development, clinical trial strategy and design, and regulatory affairs experience. Prior to founding IRISYS, he was President & CEO of Avanir Pharmaceuticals, where he was responsible for the development, regulatory approval and commercialization of Abreva®, and he led development efforts resulting in the NDA submission for Nuedexta®. Dr. Yakatan has also served as Pharmaceutics Chair at the University of Texas at Austin; Vice President for Product Development Worldwide at Warner Lambert/Parke Davis; and Founder and CEO at Tanabe Research Labs, USA. Dr. Yakatan has a long-standing commitment to community service and has been a member of the Boards of Directors for numerous not-for-profit organizations.

Dr. Yakatan received his B.S. in Pharmacy and M.S. in Pharmaceutical Chemistry from Temple University in Philadelphia, Pennsylvania. His Ph.D. was earned in Pharmaceutical Sciences from the University of Florida, in Gainesville, Florida. Dr. Yakatan has received distinguished alumnus awards from Temple University and from the University of Florida.

tags:   Biopharma Policies, Regulations     Pharmaceutical industry trends    

Disclaimer: All opinions, ideas, and thoughts expressed and posted by Contributors at platform are their own personal points of view, and do not represent neither Contributor's employers, nor

Posts by this author

The Future Of Drug Development in China

The Future Of Drug Development in China

China has been becoming a research powerhouse in many fields of science, but it still is a minor player when it comes to pharmaceuticals. However, recent developments suggest that China’s role in pharmaceutical research may change in the near future.